Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children
mRNA-1273.222 has also received FDA EUA for children and adolescents between six and 17 years of age and for adults over the age of 18 years of age.
Moderna received emergency use authorization (EUA) from FDA for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222 in children six months to five years of age.
The authorization is based on a 10 μg booster dose following a completed primary series of Moderna’s original vaccine. Additionally, the booster dose of mRNA-1273.222 contains messenger RNA (mRNA) encoding for the spike protein of BA.4/BA.5 and mRNA encoding for the original strain of the SARS-CoV-2 virus.
"With the FDA's decision, children and adolescents of all age groups in the US will now be eligible for our updated bivalent COVID-19 booster, providing families with an important protective tool as we continue through the winter months," said Stéphane Bancel, chief executive officer of Moderna, in a press release. "We appreciate the FDA's timely review."
mRNA-1273.222 has also received FDA EUA for children and adolescents between six and 17 years of age and for adults over the age of 18 years of age.
The pediatric EUA application is based on clinical trial booster data for Moderna’s original vaccine, Spikevax. This also included pre-clinical data for mRNA-1273.222 and from a Phase II/III studying mRNA-1273.214, which is another Omicron-targeting bivalent booster vaccine created by Moderna.
Moderna recently announced results from a Phase II/III trial in more than 500 adults, which highlighted that mRNA-1273.222 induced significantly higher neutralizing antibody titers against BA.4/BA.5 versus a booster dose of Moderna’s original vaccine.
Currently, a Phase II/III trial evaluating Omicron-targeting bivalent vaccines as booster and primary series in children between six months and five years of age has begun, with preliminary results expected in early 2023.
Source: Moderna Receives FDA Emergency Use Authorization For Omicron-Targeting Bivalent COVID-19 Booster Vaccine In Children 6 Months Through 5 Years Of Age. https://investors.modernatx.com/news/news-details/2022/Moderna-Receives-FDA-Emergency-Use-Authorization-for-Omicron-Targeting-Bivalent-COVID-19-Booster-Vaccine-in-Children-6-Months-Through-5-Years-of-Age/default.aspx (accessed 2022-12-13).
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
